Abstract
We evaluated the impact of applying the Infectious Diseases Society of America guidelines for febrile neutropenic patients in reducing the use of glycopeptides. Forty-five prior episodes of febrile neutropenia were compared to 97 episodes seen after application of the guidelines. Glycopeptide use was reduced from 73% to 43% of episodes (P=.0008), without changes in outcome.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Amikacin / therapeutic use
-
Anti-Bacterial Agents / therapeutic use*
-
Brazil
-
Cefepime
-
Ceftazidime / therapeutic use
-
Cephalosporins / administration & dosage
-
Child
-
Drug Therapy, Combination / therapeutic use*
-
Female
-
Fever / complications
-
Fever / drug therapy*
-
Hospitals, Teaching
-
Humans
-
Male
-
Middle Aged
-
Neutropenia / complications
-
Neutropenia / drug therapy*
-
Oxacillin / administration & dosage
-
Practice Guidelines as Topic*
-
Teicoplanin / therapeutic use
-
Treatment Outcome
-
Vancomycin / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
Teicoplanin
-
Vancomycin
-
Cefepime
-
Amikacin
-
Ceftazidime
-
Oxacillin